 |
424 Diseases |  |
807 Trials |
|
807 Trials |  |
14372 News |  |
| «12...173174175176177178179180181182183...235236» |
- | Stivarga (regorafenib) / Bayer
New P2 trial, Monotherapy, Metastases: Regorafenib Plus FOLFIRI With Irinotecan Dose Escalated in Patients With Previously Treated Metastatic Colorectal Cancer (clinicaltrials.gov) - Mar 18, 2019
P2, N=153, Recruiting, Sponsor: Kaohsiung Medical University Chung-Ho Memorial Hospital
- | New P3 trial: GRECCAR 15: Chemotherapy Followed by Pelvic Reirradiation Versus Chemotherapy Alone as Pre-operative Treatment for Locally Recurrent Rectal Cancer (clinicaltrials.gov) - Mar 18, 2019
P3, N=186, Not yet recruiting, Sponsor: University Hospital, Bordeaux
- | New P1 trial, PD(L)-1 Biomarker: Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial (clinicaltrials.gov) - Mar 18, 2019
P1, N=52, Not yet recruiting, Sponsor: OHSU Knight Cancer Institute
- | Rituxan (rituximab) / Roche
Enrollment closed, Trial completion date, Trial primary completion date: LeMLAR: Lenalidomide, MTX, Ara-C and Rituximab in Relapsed Aggressive B-cell Lymphomas (clinicaltrials.gov) - Mar 15, 2019
P1/2, N=37, Active, not recruiting, Sponsor: University Hospital, Essen
Recruiting --> Active, not recruiting | Trial completion date: Jun 2019 --> Dec 2019 | Trial primary completion date: Dec 2018 --> Jun 2019
- | Imjudo (tremelimumab) / AstraZeneca, Pfizer, Imfinzi (durvalumab) / AstraZeneca
Trial primary completion date, PD(L)-1 Biomarker, Metastases: MEDITREME: Evaluation of the Safety and the Tolerability of Durvalumab Plus Tremelimumab Combined With FOLFOX in mCRC (clinicaltrials.gov) - Mar 15, 2019
P1/2, N=48, Recruiting, Sponsor: Centre Georges Francois Leclerc
Recruiting --> Active, not recruiting | Trial completion date: Jun 2019 --> Dec 2019 | Trial primary completion date: Dec 2018 --> Jun 2019 Trial primary completion date: Aug 2019 --> Aug 2020
- | Avastin (bevacizumab) / Roche
Trial primary completion date: Evaluation of the Efficacy and the Safety of FOLFIRINOX3 Bevacizumab Treatment in Patients With Colorectal Cancer (FOLFIRINOX 3) (clinicaltrials.gov) - Mar 15, 2019
P1/2, N=55, Recruiting, Sponsor: Centre Georges Francois Leclerc
Trial primary completion date: Aug 2019 --> Aug 2020 Trial primary completion date: Nov 2018 --> Jan 2023
- || Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
Trial completion date, Trial primary completion date, Combination therapy, Metastases: GP28328: A Study of Atezolizumab Administered in Combination With Bevacizumab and/or With Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Mar 13, 2019
P1, N=240, Active, not recruiting, Sponsor: Genentech, Inc.
Trial primary completion date: Nov 2018 --> Jan 2023 Trial completion date: Dec 2018 --> Aug 2019 | Trial primary completion date: Dec 2018 --> Aug 2019
- || eftozanermin alfa (ABBV-621) / AbbVie, Apogenix
Enrollment change: A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies (clinicaltrials.gov) - Mar 13, 2019
P1, N=235, Recruiting, Sponsor: AbbVie
Trial completion date: Dec 2018 --> Aug 2019 | Trial primary completion date: Dec 2018 --> Aug 2019 N=155 --> 235
- navicixizumab (OMP-305B83) / Feng Biosci
Enrollment change, Trial termination, Trial primary completion date, Metastases: A Study of OMP-305B83 in Subjects With Metastatic Colorectal Cancer (clinicaltrials.gov) - Mar 13, 2019
P1b, N=16, Terminated, Sponsor: OncoMed Pharmaceuticals, Inc.
N=155 --> 235 N=30 --> 16 | Active, not recruiting --> Terminated | Trial primary completion date: Jan 2019 --> Sep 2018
- | Avastin (bevacizumab) / Roche
Enrollment open: The Efficacy of Bevacizumab Combined With m-FOLFOXIRI in Borderline Resectable Colorectal Liver Metastases (clinicaltrials.gov) - Mar 13, 2019
P2, N=40, Recruiting, Sponsor: National Cheng-Kung University Hospital
N=30 --> 16 | Active, not recruiting --> Terminated | Trial primary completion date: Jan 2019 --> Sep 2018 Not yet recruiting --> Recruiting
- || TRK-950 / Toray
New P1 trial: A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Mar 13, 2019
P1b, N=36, Not yet recruiting, Sponsor: Toray Industries, Inc
- | Tyvyt (sintilimab) / Eli Lilly
New P2 trial, PD(L)-1 Biomarker, IO biomarker, Metastases: TAIPD1-HCC: HAIC Combined With PD-1 Inhibitor in Potentially Resectable Locally Advanced HCC (clinicaltrials.gov) - Mar 10, 2019
P2, N=40, Not yet recruiting, Sponsor: Sun Yat-sen University
- | Trial completion date, Metastases: FLOT4: 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced, Resectable Gastric Cancer (clinicaltrials.gov) - Mar 8, 2019
P2/3, N=716, Active, not recruiting, Sponsor: Krankenhaus Nordwest
Not yet recruiting --> Recruiting Trial completion date: Sep 2018 --> May 2019
- | Trial completion date, Trial primary completion date: NEPAFOX: Randomized Multicenter Phase II/III Study With Adjuvant Gemcitabine Versus Neoadjuvant / Adjuvant FOLFIRINOX for Resectable Pancreas Carcinoma (clinicaltrials.gov) - Mar 8, 2019
P2/3, N=40, Active, not recruiting, Sponsor: Krankenhaus Nordwest
Trial completion date: Sep 2018 --> May 2019 Trial completion date: Jan 2019 --> Jul 2019 | Trial primary completion date: Jan 2019 --> Jul 2019
- | thioguanine / Generic mfg., dasatinib / Generic mfg.
Trial suspension: AALL1131: Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations (clinicaltrials.gov) - Mar 7, 2019
P3, N=5956, Suspended, Sponsor: National Cancer Institute (NCI)
Trial completion date: Jan 2019 --> Jul 2019 | Trial primary completion date: Jan 2019 --> Jul 2019 Recruiting --> Suspended
- | Tecentriq (atezolizumab) / Roche
Trial completion date, Trial primary completion date, Mismatch repair, Tumor mutational burden, PD(L)-1 Biomarker: Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair (clinicaltrials.gov) - Mar 7, 2019
P3, N=700, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Suspended Trial completion date: Jul 2020 --> Dec 2020 | Trial primary completion date: Jul 2020 --> Dec 2020
- || Vectibix (panitumumab) / Amgen
Trial completion date, Trial primary completion date: PanaMa: Maintenance Therapy With 5-FU/FA Plus Panitumumab vs. 5-FU/FA Alone After Prior Induction and Re-induction After Progress for 1st-line Treatment of Metastatic Colorectal Cancer (clinicaltrials.gov) - Mar 6, 2019
P2, N=380, Recruiting, Sponsor: AIO-Studien-gGmbH
Trial completion date: Jul 2020 --> Dec 2020 | Trial primary completion date: Jul 2020 --> Dec 2020 Trial completion date: Jun 2018 --> Jun 2020 | Trial primary completion date: Dec 2017 --> Dec 2019
- | Trial completion: Phase II Trial of Sorafenib Combined With Concurrent HAIC for Hepatocellular Carcinoma (clinicaltrials.gov) - Mar 6, 2019
P2, N=35, Completed, Sponsor: Sun Yat-sen University
Trial completion date: Jun 2018 --> Jun 2020 | Trial primary completion date: Dec 2017 --> Dec 2019 Recruiting --> Completed
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Enrollment closed, Surgery, Metastases: PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery (clinicaltrials.gov) - Mar 5, 2019
P2/3, N=1194, Active, not recruiting, Sponsor: Alliance for Clinical Trials in Oncology
Recruiting --> Completed Recruiting --> Active, not recruiting
- | dilpacimab (ABT-165) / AbbVie
Trial completion date, Metastases: A Study of ABT-165 Plus FOLFIRI vs Bevacizumab Plus FOLFIRI in Subjects With Metastatic Colorectal Cancer Previously Treated With Fluoropyrimidine, Oxaliplatin and Bevacizumab (clinicaltrials.gov) - Mar 4, 2019
P2, N=100, Recruiting, Sponsor: AbbVie
Recruiting --> Active, not recruiting Trial completion date: Aug 2020 --> May 2021
- || Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
New P2 trial, Combination therapy, Metastases: Liposomal Irinotecan in Combination With Oxaliplatin, Leucovorin, and 5-fluorouracil for Patients With Locally Advanced Pancreatic Carcinoma: (clinicaltrials.gov) - Mar 4, 2019
P2, N=28, Not yet recruiting, Sponsor: Big Ten Cancer Research Consortium
- | Avastin (bevacizumab) / Roche, Vectibix (panitumumab) / Amgen
Enrollment closed, Trial completion date, Trial primary completion date: CCRe-IV: Resection vs no Resection of the Primary in Colorectal Cancer With Unresectable Metastases (clinicaltrials.gov) - Mar 1, 2019
P4, N=336, Active, not recruiting, Sponsor: Hospital Universitari de Bellvitge
Trial completion date: Aug 2020 --> May 2021 Recruiting --> Active, not recruiting | Trial completion date: Nov 2018 --> Jun 2019 | Trial primary completion date: Nov 2018 --> Jun 2017
- | Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
Enrollment open, Trial completion date, Trial primary completion date: AALL1621: Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Mar 1, 2019
P2, N=53, Recruiting, Sponsor: Children's Oncology Group
Recruiting --> Active, not recruiting | Trial completion date: Nov 2018 --> Jun 2019 | Trial primary completion date: Nov 2018 --> Jun 2017 Active, not recruiting --> Recruiting | Trial completion date: Jun 2019 --> Sep 2019 | Trial primary completion date: Jun 2019 --> Sep 2019
- | Trial completion, Enrollment change, Trial completion date, Surgery: GCC 1324: Borderline Pancreas Study: FOLFIRINOX +SBRT (clinicaltrials.gov) - Feb 28, 2019
P1, N=8, Completed, Sponsor: University of Maryland
Active, not recruiting --> Recruiting | Trial completion date: Jun 2019 --> Sep 2019 | Trial primary completion date: Jun 2019 --> Sep 2019 Recruiting --> Completed | N=20 --> 8 | Trial completion date: Dec 2020 --> Sep 2018
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Trial completion, Enrollment change, Trial completion date: GCC 1314: Pelvic Radiotherapy With Concurrent Neoadjuvant FOLFOX for Patients With Newly Diagnosed Rectal Adenocarcinoma (clinicaltrials.gov) - Feb 28, 2019
P2, N=3, Completed, Sponsor: University of Maryland
Recruiting --> Completed | N=20 --> 8 | Trial completion date: Dec 2020 --> Sep 2018 Recruiting --> Completed | N=30 --> 3 | Trial completion date: Dec 2021 --> Oct 2018
- | Trial completion date, Trial primary completion date, Monotherapy, Metastases: Study of Favezelimab (MK-4280) as Monotherapy and in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy or Lenvatinib (MK-7902) AND Favezelimab/Pembrolizumab (MK-4280A) as Monotherapy in Adults With Advanced Solid Tumors (MK-4280-001) (clinicaltrials.gov) - Feb 28, 2019
P1, N=408, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Completed | N=30 --> 3 | Trial completion date: Dec 2021 --> Oct 2018 Trial completion date: Jul 2021 --> May 2022 | Trial primary completion date: Jul 2021 --> May 2022
- | Trial completion date, Trial primary completion date, Metastases: MATURE01: Modified Folinic Acid-Fluorouracil-Oxaliplatin Regimen + Capecitabine for Elderly With Metastatic Gastric Cancer (clinicaltrials.gov) - Feb 27, 2019
P=N/A, N=47, Recruiting, Sponsor: International Group of Endovascular Oncology
Trial completion date: Jul 2021 --> May 2022 | Trial primary completion date: Jul 2021 --> May 2022 Trial completion date: May 2016 --> May 2022 | Trial primary completion date: Nov 2015 --> Nov 2021
- ||| Tedopi (OSE 2101) / OSE Immunotherapeutics
Enrollment open, Combination therapy, Metastases: TEDOPAM: Maintenance With OSE2101 Plus FOLFIRI, or FOLFIRI After FOLFIRINOX-based Induction Therapy in Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov) - Feb 27, 2019
P2, N=156, Recruiting, Sponsor: GERCOR - Multidisciplinary Oncology Cooperative Group
Trial completion date: May 2016 --> May 2022 | Trial primary completion date: Nov 2015 --> Nov 2021 Not yet recruiting --> Recruiting
- HyperAcute Pancreas (algenpantucel-L) / Lumos Pharma
Trial primary completion date: Immunotherapy and SBRT Study in Borderline Resectable Pancreatic Cancer (clinicaltrials.gov) - Feb 26, 2019
P2, N=10, Terminated, Sponsor: NewLink Genetics Corporation
Not yet recruiting --> Recruiting Trial primary completion date: Dec 2016 --> Jun 2016
- |||| misetionamide (GP-2250) / Panavance Therap
New P1/2 trial, Combination therapy, Metastases: Trial to Evaluate Safety and Tolerability of GP-2250 in Combination With Gemcitabine (clinicaltrials.gov) - Feb 26, 2019
P1/2, N=54, Recruiting, Sponsor: Geistlich Pharma AG
- ||||||||| HyperAcute Pancreas (algenpantucel-L) / Lumos Pharma
Trial termination, Trial primary completion date, Metastases: Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer (clinicaltrials.gov) - Feb 25, 2019
P3, N=302, Terminated, Sponsor: NewLink Genetics Corporation
Trial primary completion date: Dec 2016 --> Jun 2016 Active, not recruiting --> Terminated | Trial primary completion date: Dec 2016 --> Jul 2016; Company decision
- | GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells) / Novartis, Yervoy (ipilimumab) / BMS
Enrollment closed, Trial completion date, Trial primary completion date, Combination therapy, Metastases: FOLFIRINOX Followed by Ipilimumab With Pancreatic Tumor Vaccine in Treatment of Metastatic Pancreatic Cancer (clinicaltrials.gov) - Feb 25, 2019
P2, N=83, Active, not recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Active, not recruiting --> Terminated | Trial primary completion date: Dec 2016 --> Jul 2016; Company decision Suspended --> Active, not recruiting | Trial completion date: Dec 2019 --> Jan 2021 | Trial primary completion date: Jan 2019 --> Jan 2021
- davamotecan pegadexamer (EP0057) / Ellipses Pharma
Enrollment change, Trial completion date, Trial termination, Combination therapy, Metastases: Alternative Dosing for CRLX101(NLG207) Alone, With Avastin and With mFOLFOX6 in Advanced Solid Tumors (clinicaltrials.gov) - Feb 25, 2019
P1, N=41, Terminated, Sponsor: NewLink Genetics Corporation
Suspended --> Active, not recruiting | Trial completion date: Dec 2019 --> Jan 2021 | Trial primary completion date: Jan 2019 --> Jan 2021 N=61 --> 41 | Trial completion date: Dec 2017 --> May 2018 | Active, not recruiting --> Terminated; Company decision
- | Enrollment closed, Adverse events, Combination therapy, Metastases: Side Effects to FOLFOXIRI + Tocotrienol/Placebo as First Line Treatment of Metastatic Colorectal Cancer (clinicaltrials.gov) - Feb 25, 2019
P2, N=70, Active, not recruiting, Sponsor: Vejle Hospital
N=61 --> 41 | Trial completion date: Dec 2017 --> May 2018 | Active, not recruiting --> Terminated; Company decision Recruiting --> Active, not recruiting
- | Trial completion date, Trial primary completion date: Colon Neoadjuvant FOLFOXIRI Study (clinicaltrials.gov) - Feb 22, 2019
P2, N=40, Recruiting, Sponsor: Chinese University of Hong Kong
Recruiting --> Active, not recruiting Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Dec 2018 --> Dec 2019
- | Zaltrap (ziv-aflibercept IV) / Sanofi
Enrollment closed, Enrollment change, Trial primary completion date, Metastases: MINOAS: Trial in Metastatic Colorectal Cancer With FOLFIRI Plus Aflibercept as First Line Treatment (clinicaltrials.gov) - Feb 22, 2019
P2, N=31, Active, not recruiting, Sponsor: Hellenic Oncology Research Group
Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Dec 2018 --> Dec 2019 Recruiting --> Active, not recruiting | N=89 --> 31 | Trial primary completion date: Jan 2019 --> Oct 2018
- || Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Trial completion date, Trial primary completion date, Metastases: MATEO: Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer (clinicaltrials.gov) - Feb 20, 2019
P2, N=400, Recruiting, Sponsor: AIO-Studien-gGmbH
Recruiting --> Active, not recruiting | N=89 --> 31 | Trial primary completion date: Jan 2019 --> Oct 2018 Trial completion date: Sep 2018 --> Jul 2020 | Trial primary completion date: Sep 2018 --> Apr 2020
- || Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
Trial completion date, Trial primary completion date, Metastases: AIO-NIFE-trial: Nal-IRI With 5-fluorouracil (5-FU) and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Biliary-tract Cancer (clinicaltrials.gov) - Feb 20, 2019
P2, N=92, Recruiting, Sponsor: AIO-Studien-gGmbH
Trial completion date: Sep 2018 --> Jul 2020 | Trial primary completion date: Sep 2018 --> Apr 2020 Trial completion date: Jan 2024 --> Jul 2023 | Trial primary completion date: Oct 2018 --> Dec 2019
- | Avastin (bevacizumab) / Roche
Enrollment closed, Trial completion date, Trial primary completion date, Combination therapy: Avastin/FOLFIRI in Combination With Curcumin in Colorectal Cancer Patients With Unresectable Metastasis (clinicaltrials.gov) - Feb 19, 2019
P2, N=50, Active, not recruiting, Sponsor: Gachon University Gil Medical Center
Trial completion date: Jan 2024 --> Jul 2023 | Trial primary completion date: Oct 2018 --> Dec 2019 Enrolling by invitation --> Active, not recruiting | Trial completion date: Mar 2019 --> Dec 2019 | Trial primary completion date: May 2017 --> Jun 2019
- | Avastin (bevacizumab) / Roche, Vectibix (panitumumab) / Amgen
Trial primary completion date: CAIRO5: Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only Metastases (clinicaltrials.gov) - Feb 18, 2019
P3, N=564, Recruiting, Sponsor: Dutch Colorectal Cancer Group
Enrolling by invitation --> Active, not recruiting | Trial completion date: Mar 2019 --> Dec 2019 | Trial primary completion date: May 2017 --> Jun 2019 Trial primary completion date: Jul 2020 --> Dec 2020
- |||| andecaliximab (GS-5745) / Gilead
Trial completion date, Trial primary completion date, Metastases: GAMMA-1: Andecaliximab With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov) - Feb 18, 2019
P3, N=432, Active, not recruiting, Sponsor: Gilead Sciences
Trial primary completion date: Jul 2020 --> Dec 2020 Trial completion date: Dec 2023 --> May 2019 | Trial primary completion date: Aug 2018 --> May 2019
- | Trial completion, Trial primary completion date: Modified FOLFIRINOX for Gemcitabine Refractory Pancreatic Cancer: A Phase II Multicenter Trial (clinicaltrials.gov) - Feb 18, 2019
P2, N=50, Completed, Sponsor: Yonsei University
Trial completion date: Dec 2023 --> May 2019 | Trial primary completion date: Aug 2018 --> May 2019 Not yet recruiting --> Completed | Trial primary completion date: Dec 2016 --> Mar 2017
- || Zaltrap (ziv-aflibercept IV) / Sanofi
Trial primary completion date, Metastases: RIA: Induction FOLFOX With or Without Aflibercept Followed by Chemoradiation in High Risk Locally Advanced Rectal Cancer (clinicaltrials.gov) - Feb 16, 2019
P2, N=180, Active, not recruiting, Sponsor: Grupo Espanol Multidisciplinario del Cancer Digestivo
Not yet recruiting --> Completed | Trial primary completion date: Dec 2016 --> Mar 2017 Trial primary completion date: Sep 2018 --> Dec 2019
- | Bylantra (devimistat) / Cornerstone Pharma
Trial completion date, Trial primary completion date, Combination therapy, Metastases: CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer (clinicaltrials.gov) - Feb 16, 2019
P1, N=21, Active, not recruiting, Sponsor: Wake Forest University Health Sciences
Trial primary completion date: Sep 2018 --> Dec 2019 Trial completion date: Jan 2019 --> May 2019 | Trial primary completion date: Jan 2019 --> May 2019
- | Trial completion date, Metastases: Phase II Study of 5-FU, Oxaliplatin Plus Dasatinib in Metastatic Pancreatic Adenocarcinoma (clinicaltrials.gov) - Feb 16, 2019
P2, N=58, Active, not recruiting, Sponsor: University of Florida
Trial completion date: Jan 2019 --> May 2019 | Trial primary completion date: Jan 2019 --> May 2019 Trial completion date: Jan 2019 --> Jul 2019
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Trial completion, Trial completion date, Combination therapy, Metastases: Efficacy and Safety of Aflibercept in Combination With FOLFIRI Chemotherapy as 1st Line Treatment for Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Feb 15, 2019
P2, N=41, Completed, Sponsor: Federation Francophone de Cancerologie Digestive
Trial completion date: Jan 2019 --> Jul 2019 Recruiting --> Completed | Trial completion date: Nov 2017 --> Jul 2017
- | NN1213 / Novo Nordisk
Enrollment open, Surgery: A021501: Combination Chemotherapy With or Without Hypofractionated Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer (clinicaltrials.gov) - Feb 15, 2019
P2, N=134, Recruiting, Sponsor: Alliance for Clinical Trials in Oncology
Recruiting --> Completed | Trial completion date: Nov 2017 --> Jul 2017 Suspended --> Recruiting
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Trial completion date, Trial initiation date, Trial primary completion date, Metastases: High-dose FOLFIRI in Advanced Colorectal Cancer Patients With Wild-type UGT1A1*6 and *28 (clinicaltrials.gov) - Feb 15, 2019
P2, N=90, Recruiting, Sponsor: Shanghai Changzheng Hospital
Suspended --> Recruiting Trial completion date: Nov 2021 --> Mar 2022 | Initiation date: Nov 2018 --> Mar 2019 | Trial primary completion date: Nov 2018 --> Mar 2019
- || epacadostat (INCB024360) / Incyte
Phase classification, Enrollment change: Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer (clinicaltrials.gov) - Feb 15, 2019
P1, N=39, Not yet recruiting, Sponsor: Washington University School of Medicine
Trial completion date: Nov 2021 --> Mar 2022 | Initiation date: Nov 2018 --> Mar 2019 | Trial primary completion date: Nov 2018 --> Mar 2019 Phase classification: P1/2 --> P1 | N=57 --> 39
- | EGFR bi-armed autologous activated T cells / Barbara Ann Karmanos Cancer Institute
Trial completion date, Trial primary completion date, Metastases: Anti-CD3 x Anti-Erbitux (clinicaltrials.gov) - Feb 12, 2019
P1, N=30, Active, not recruiting, Sponsor: Barbara Ann Karmanos Cancer Institute
Phase classification: P1/2 --> P1 | N=57 --> 39 Trial completion date: Jun 2019 --> Jun 2021 | Trial primary completion date: Jan 2019 --> Jan 2021